Disease-specific autoaggressive T-cell

Disease-specific autoaggressive T-cells are a subset of T-lymphocytes that have escaped central or peripheral tolerance mechanisms and recognize self-antigens as foreign [Nature Reviews Immunology, 2020]. These cells are the primary mediators of tissue damage in autoimmune diseases such as multiple sclerosis, type 1 diabetes, and rheumatoid arthritis [Science Translational Medicine, 2016]. Upon activation, they migrate to specific organs, secrete pro-inflammatory cytokines like IFN-gamma and IL-17, and orchestrate a destructive immune response [Frontiers in Immunology, 2021]. Modern therapeutic strategies focus on the selective depletion or modulation of these cells to restore immune homeostasis without causing broad immunosuppression. Drugs like teplizumab target the CD3 complex to modulate these cells in early-stage type 1 diabetes, while antigen-specific therapies aim to induce anergy or regulatory T-cell differentiation [NEJM, 2019]. The identification of these cells often relies on MHC-peptide tetramer technology and high-throughput TCR sequencing to track pathogenic clones [Nature Methods, 2013]. Challenges in targeting these cells include their low frequency in peripheral blood and the potential for epitope spreading, where the immune response expands to new self-antigens over time. Successfully neutralizing these autoaggressive populations represents a major goal in immunology, offering the potential for long-term disease remission [The Lancet, 2021].

Other names

Autoreactive T-cellsPathogenic T-cellsSelf-reactive T-lymphocytesAutoimmune T-cells

Selective depletion of pathogenic T-cell clones, induction of immune tolerance, blockade of T-cell costimulation, and inhibition of T-cell trafficking to target tissues.